Closantel, an FDA-approved veterinary drug, suppresses PEDV replication via targeting main protease

values of 1.49 ± 0.38 μM and 4.32 ± 0.53 μM, respectively, and exhibits minimal cytotoxicity. Remarkably, Closantel triggers interferon secretion and activates JAK-STAT signaling pathways via phosphorylation of STAT1 and STAT2, establishing a dual antiviral mechanism. In summary, Closantel holds promise as a potential lead compound for developing targeted therapies against PEDV infection.